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ABSTRACT 
Several studies have been in favor of fungi as a possible pathogenesis of chronic rhinosinusitis (CRS); however, 
to date, there is no scientific consensus about the use of antifungal agents in disease management. The aim of the 
present study was to investigate the efficacy of intranasal fluconazole in improving disease symptoms and objec-
tive outcomes of patients with CRS. A randomized, double-blind, placebo-controlled study was conducted on 54 
patients who were diagnosed with CRS and had not been responsive to routine medical treatments. They were 
randomly assigned to receive either fluconazole nasal drop 0.2 % or placebo in addition to the standard regimen 
for a duration of 8 weeks. Patients’ outcomes were evaluated according to Sino-Nasal Outcome Test 20 (SNOT-
20), endoscopic scores, and Computed Tomography (CT) scores. No statistically significant difference was 
found in SNOT-20 (p = 0.201), endoscopic (p = 0.283), and CT scores (p = 0.212) of the patients at baseline and 
after 8-week course of treatment between drug and placebo group. Similar to many studies, the use of topical 
antifungal treatment for patients with CRS was not shown to be significantly effective. However, further studies 
are needed to obtain high levels of consistent evidence in order to arrive at a decision whether antifungal therapy 
is effective in management of CRS or not. 
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INTRODUCTION 
Chronic Rhinosinusitis (CRS) is defined 
as inflammation of paranasal sinuses, nasal 
cavity and mucosa which lasts more than 12 
weeks and is characterized by nasal block-
age, or congestion, nasal discharge (anterior/ 
posterior nasal drip), and/or facial pain or 
pressure, and/or impaired or reduced sense of 
smell (Fokkens et al., 2012; Resenfeld et al., 
2007). 
According to the 2011 National Health 
Interview Survey (NHIS), 12.8 % of adults 
aged 18 or over were diagnosed with sinusi-
tis in the United States. Considering the age 
group, prevalence of sinusitis was highest 
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among 65-74 year olds (16.4 %), and lowest 
among the age group of 18-44 (9.8 %). 
Comparing with prevalence of chronic bron-
chitis (4.4 %), hay fever (7.3 %), asthma 
(8.2 %), diabetes (9 %), chronic joint symp-
toms (29.8 %) (Schiller et al., 2012), it can 
be concluded that sinusitis is indeed a very 
common condition with high disease preva-
lence (Hamilos, 2011; Bhattacharyya et al., 
2011). 
CRS has been found to have a negative 
impact on mood, energy level, physical func-
tion, and quality of life of the individuals 
(Gliklich and Metson, 1995; Wabnitz et al., 
2005; Piromchai et al., 2013). The impact of 
CRS on quality of life, measured by short 
form 36 scale scores (SF-36 scale scores) 
was found to be comparable with or worse 
than that of other chronic conditions such as 
chronic obstructive pulmonary disease 
(COPD), congestive heart failure (CHF), and 
back pain (Metson and Gliklich, 2000). 
Moreover, it has been found that rhinitis 
symptoms have resulted in school absence in 
26.1 % and frequent interference with daily 
activities in 2.7 % of the patients (Torfi et 
al., 2015). Several factors contribute to the 
high economic impact of CRS. These in-
clude: being a chronic condition with no 
universal cure, having frequent exacerbations 
of symptoms which requires acute treatments 
in addition to the chronic ones already in 
place, having high impact on quality of life, 
having incomplete symptom control which 
results in seeking additional therapies to get 
relief, and difficulty in accurately diagnosing 
the condition without radiologic or diagnos-
tic procedures (Bhattacharyya et al., 2011). 
Etiology of CRS is not clearly under-
stood. Several factors have been identified to 
contribute to the development of CRS. These 
include bacterial infection, allergens, struc-
tural abnormalities such as deviated septums, 
biofilm bacterial infections, and Samter’s 
triad (salicylate sensitivity, asthma, and nasal 
polyps) (Ryan, 2008; Skadding et al., 2008; 
Ramadan et al., 2005; Palmer, 2005). There 
is a growing body of evidence supporting the 
idea that fungi may indeed play a role in eti-
ology of CRS (Ponikau et al., 1999; Hashe-
mian et al., 2012; Loung and Marpel, 2005; 
Lebowitz et al., 2002; Hafidh et al., 2007). 
However, positive fungal cultures have been 
found in the nasal mucosa of healthy indi-
viduals as well as patients with CRS (Lack-
ner et al., 2005). Moreover, allergic and non-
allergic forms of non-invasive fungal in-
flammation have already been identified 
(Loung and Marpel, 2005). Although several 
studies have been in favor of fungi as a pos-
sible pathogenesis of CRS, to date, there is 
no scientific consensus regarding the use of 
antifungal agents in the management of CRS 
(Ebbens et al., 2007). One should consider 
that Allergic fungal rhinosinusitis (AFRS), a 
recognized type of rhinosinusitis (Saravanan 
et al., 2006), is an immune-modulated dis-
ease entity and a clear immunological differ-
ence between AFRS and CRS patients has 
been manifested (Glass and Amedee, 2011; 
Hutcheson et al., 2010). 
There is no consensus on the definitive 
guidelines for the treatment of CRS (Ben-
ninger et al., 2003). According to the 2012 
European Position Paper on Rhinosinusitis 
and Nasal Polyps, treatment evidence and 
recommendations for adults with CRS in-
clude the use of topical steroids, nasal saline 
irrigation, oral antibiotic therapy (less than 4 
weeks during exacerbations and more than 
12 weeks especially when IgE is not elevat-
ed), oral steroids, mucolytics, proton pump 
inhibitors (PPIs), oral and topical decongest-
ants, probiotics, immunotherapy, and sys-
temic and topical antifungals (Fokkens et al., 
2012). However, the use of a number of the 
above mentioned medication including sys-
temic and topical antifungals remains con-
troversial (Ebbens et al., 2007; Sacks et al., 
2012). 
Taking into account, the high disease 
prevalence, and levels of impact that CRS 
has on health economy and quality of life of 
the individuals together with its unknown 
etiology, and existence of no universal cure, 
one may recognize the urgent need for con-
ducting well-designed clinical trials in order 
to arrive at high levels of evidence to im-
prove clinical symptoms and objective out-
comes of patients with CRS. Considering the 
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emergence of the growing evidence regard-
ing the role of fungi in etiology of CRS, to 
date, little randomized clinical trials (RCTs) 
have been done to investigate the effective-
ness of topical antifungals in symptom re-
duction and improvement of disease out-
comes. For instance, the effects of topical 
application of amphotericin B in patients 
with CRS was studied in a randomized, dou-
ble-blind, placebo-controlled study. Accord-
ing to the results, intranasal amphotericin B 
had indeed reduced intranasal mucosal thick-
ening on computed tomography (CT) scan 
and nasal endoscopy scores (Ponikau et al, 
2005). However, according to the results of 
another randomized placebo-controlled trial, 
administration of amphotericin B nasal spray 
to patients who underwent surgery for their 
nasal polyposis did not lead to significant 
improvements in clinical symptoms in com-
parison with the placebo group (Gerlinger et 
al., 2009). 
Yet, fluconazole has been found to be far 
less toxic than amphotericin B in numerous 
studies (Kontoyiannis et al., 2001; Viscoli et 
al., 1996; Abele-Horn et al., 1996; Malik et 
al., 1997). Thus, the aim of the present study 
was to investigate the efficacy of topical flu-
conazole 0.2 % in management of patients 
with chronic rhinosinusitis with evaluation 
of Sino-Nasal Outcome Test (SNOT-20), CT 
scores, and endoscopic scores as outcome 
measures. 
 
MATERIALS AND METHODS 
Fifty four patients who were diagnosed 
with CRS according to the American Acad-
emy of Otolaryngology-Head and Neck sur-
gery (AAO-HNS) criteria, and had not been 
responsive to routine medical treatments en-
rolled in a randomized, double-blind, place-
bo-controlled study. Patients who were preg-
nant, lactating or suffered from a major ill-
ness (such as cardiovascular disease, acute 
renal or liver disease, cancer or active malig-
nancy) were excluded from the study. The 
present study was approved by ethics com-
mittee of Hamadan University of Medical 
Sciences (Number: 16-35-9-56549) and all 
patients participated in the study were in-
formed of the study procedure and signed 
written consent forms. Moreover, the study 
was registered in Iranian Clinical Trials Cen-
ter (IRCT) (Registration Number: 
IRCT138811063186N1). The present study 
was conducted at Hamadan University of 
Medical Sciences, Besat Hospital and from 
54 patients who initially entered the study, 
48 were available for follow ups. Thus, 48 
patients included in the study. Sample size 
selection was done according to a previous 
study of topical antifungal treatment in CRS 
(Ponikau et al., 2005). 
The patients were randomly assigned to 
receive either Fluticasone nasal spray 
50 mcg (2 puffs per day, 2 times a day) plus 
fluconazole nasal drop 0.2 % (12 drops per 
day, 2 times a day) or Fluticasone nasal 
spray 50 mcg (2 puffs per day, 2 times a day) 
plus placebo for a duration of 8 weeks. Ran-
domization was done by tossing a coin by an 
independent third party (ward secretary). Pa-
tients’ outcomes were evaluated according to 
SNOT-20, CT, and endoscopic scores which 
were obtained at baseline and the end of 8 
weeks period by a senior otolaryngologist. 
Any possible side effects were recorded. As 
there is no available fluconazole nasal drop 
in the global pharmaceutical market, it was 
prepared in pharmaceutics department of 
Tehran University of Medical Sciences. 
First, standard powder of fluconazole (puri-
fied fluconazole) was procured from Darou 
Pakhsh Pharma Chem. Co. (Tehran, Iran). 
Although, fluconazole is slightly soluble in 
water, a water-based solution of fluconazole 
was prepared in order to decrease possible 
side effects of the prepared formulation and 
improve patient safety in the clinical trial. 
No preservative was used due to possible 
irritating effects of a preservative on nasal 
mucosa. Moreover, the drug was supposed to 
be used in short intervals; therefore, there 
was probably no need for the use of preserv-
ative in the formulation. All prepared formu-
lations were then filtered through 0.22 mi-
cron filters. Placebo was prepared in the 
same manner, except that distilled water was 
used instead of the active ingredient. In order 
to test the stability of the formulations, high 
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performance liquid chromatography (HPLC) 
was used, and room temperature and refrig-
erated stability data were obtained. After a 
month period, 91 % of the initial active in-
gredient was detected. The obtained results 
confirmed the stability of the formulation. 
After completing all required tests, drug 
formulations were filled in 10 cc bottles ob-
tained from SinaDarou Co. (Tehran, Iran). 
All procedure was done under sterile condi-
tions. Two types of bottles were prepared, 
one filled with the drug formulation and the 
other with the same amount of distilled wa-
ter. Thus, drug and placebo were exactly 
identical in terms of their appearance and 
could not be identified neither by the clini-
cian nor the patient. Moreover, the bottles 
were coded by a third party who wrote down 
the codes in a table and the third party him-
self decoded the bottles at the end of the 
study. Data obtained from SNOT-20 scores, 
CT and endoscopic scores were analyzed by 
SPSS 18.0 software. Paired t-tests, inde-
pendent sample t-tests and General Linear 
Model (GLM) were used to evaluate the pos-
sible differences between the drug and pla-
cebo group. P-values less than 0.05 were as-
sumed significant. 
 
RESULTS 
The study included 48 of the 54 patients 
initially enrolled. Three patients were ex-
cluded from the treatment and 3 patients 
from the placebo group. One of the patients 
was excluded from the treatment group due 
to exacerbation of the disease and two others 
were voluntarily refused to continue the 
study. Three patients excluded from the pla-
cebo group were also voluntarily refused to 
continue the study. 
No significant differences were found be-
tween the two groups regarding age, gender, 
smoking status and having nasal polyps be-
fore the study (P > 0.05). Demographics of 
the patients are shown in Table 1. 
Table 1: Demographics of the patients  
Treatment Placebo p-
Value 
Mean Age (years) 38.25 (± 
1.70 SD) 
39.75 (± 
3.195 SD) 
0.280 
Male 
Female 
18 
6 
16 
8 0.680 
Smokers 
Non-Smokers 
3 
21 
2 
22 1.00 
Patients with 
Polyps 
Patients without 
Polyps 
9 
 
15 
12 
 
12 0.680 
SD: Standard Deviation 
 
 
Outcome measures before and after the 
treatment in drug and placebo groups are 
shown in Table 2. Differences between the 
obtained SNOT-20 scores at baseline and the 
end of 8 weeks were found not to be signifi-
cant between the two study groups (p > 
0.05). Moreover, the obtained endoscopic 
scores at baseline and the end of 8 weeks 
treatment showed no significant difference 
between the two groups (p > 0.05).  Differ-
ences between the obtained CT-scan scores 
at baseline and the end of 8 weeks were cal-
culated not to be significant between the two 
groups as well (p > 0.05).  
 
 
Table 2: Outcome measures before and after the 
treatment 
 Treatment Placebo p-Value 
Pre-SNOT-20 36.29 41.33 0.28 
Post-SNOT-
20 27.25 28.71 0.76 
SNOT-20 
Mean Differ-
ence 
9.04 12.62 0.201 
Pre- Endo-
scopy score 3.13 3.08 0.88 
Post- Endo-
scopy score 2.42 2.04 0.36 
Endoscopy 
score Mean 
Difference 
0.71 1.04 0.283 
Pre- CT  
scan score 14.42 17.21 0.19 
Post- CT 
scan score 13.58 15.21 0.43 
CT scan 
score Mean 
Difference 
0.83 2.00 0.212 
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Moreover, topical fluconazole 0.2 % was 
found to have a good safety profile with in-
cidence of slight burning sensations in only 2 
of the cases. 
 
DISCUSSION 
There is no consensus on definitive 
treatment guidelines for management of CRS 
probably due to the lack of agreement about 
the etiology of the disease (Benninger et al., 
2003). Some studies have focused on the ef-
fects of topical antifungal therapy namely 
amphotericin B in improving clinical symp-
toms and outcomes of CRS patients. Accord-
ing to our knowledge, to date, no one has 
studied the efficacy of topical (nasal drop) 
fluconazole treatment which is known to be 
far less toxic than antifungal amphotericin B 
in patients with CRS. Results of the present 
study showed no significant difference in 
outcome measures between the drug and pla-
cebo group at baseline and the end of 8 
weeks period. In other words, no improve-
ment was observed in SNOT-20, endoscopic, 
and CT scores of the patients before and af-
ter treatment. The obtained results were in 
accordance with the findings of some clinical 
trials investigating the efficacy of topical an-
tifungal treatment in CRS. 
In a prospective pilot study, application 
of topical nasal fluconazole spray in addition 
to systemic steroids and itraconazole was 
investigated on 16 patients with allergic fun-
gal sinusitis (AFRS). According to the re-
sults, improvement or stabilization of disease 
without significant side effects was ob-
served. Thus, the authors concluded that, 
topical fluconazole application may help pa-
tients with AFRS (Jen et al., 2004). Never-
theless, it should be considered that allergic 
fungal rhinosinusitis is an immune-
modulated disease entity and a clear immu-
nological difference between AFRS and 
CRS patients has been manifested (Hutche-
son et al., 2010). 
The effects of different topical nasal 
therapies in management of CRS have been 
a topic of investigation. According to a re-
cent systematic review, there was insuffi-
cient data regarding potential benefits of top-
ical antibiotics in patients with CRS, alt-
hough topical steroids were found to be ben-
eficial in management of CRS in patients 
with nasal polyps (Wei et al., 2013). As 
thyme and honey are reported to have anti-
bacterial and antifungal properties, the ef-
fects of thyme honey nasal spray in man-
agement of CRS was investigated in a novel 
randomized, double-blind, placebo-controll-
ed clinical trial. Similar to the present study, 
no significant changes were observed in out-
come measures between the drug and place-
bo group. Nevertheless, a greater reduction 
in endoscopic scores was observed in the 
treatment group (Hashemian et al., 2015). 
Effects of topical antifungal therapy 
namely amphotericin B in improving clinical 
symptoms and outcomes of patients with 
CRS have been investigated in some studies. 
For instance, Weschta et al. (2004) studied 
the efficacy of intranasal amphotericin B in 
management of CRS in patients with nasal 
polyps over a course of 8-week treatment. 
Symptom scores were significantly worse 
after amphotericin B therapy; however, simi-
lar to the present study, other outcome 
measures were found not to differ remarka-
bly between the drug and placebo groups. 
Results of another study on the efficacy of 
intranasal amphotericin B treatment showed 
significant reduction in inflammatory muco-
sal thickening on both CT scan and nasal en-
doscopy as well as decreased levels of in-
tranasal markers for eosinophilic inflamma-
tion in the drug group in comparison with the 
placebo group. Nevertheless, no significant 
difference was reported between drug and 
placebo group in improving SNOT-20 scores 
at baseline and after treatment period (Poni-
kau et al., 2005). The mentioned study is 
probably the only clinical trial that showed 
significant improvement in patients’ out-
comes after antifungal therapy. When the 
mentioned study is compared with similar 
randomized, double-blind, placebo-controll-
ed trials of amphotericin B, one may notice 
that it was conducted over a longer period of 
time (24 weeks) and longer use of antifungal 
therapy may indeed have had an impact on 
outcomes of the patients. Moreover, one may 
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take into account that only radiographic find-
ings (CT and endoscopic scores) showed 
significant improvement and symptom re-
duction (SNOT-20 scores) after treatment 
was not significant. Results of another clini-
cal trial on the efficacy of intranasal ampho-
tericin B showed no significant difference in 
the Mean visual analogue scale (VAS) 
scores, nasal endoscopy scores, and Short 
Form-36 and Rhinosinusitis Outcome Meas-
ure-31 (RSOM-31) of the drug and placebo 
group (Ebbens et al., 2006). However, one 
might consider the dosage of amphotericin B 
used in the mentioned study as the major 
weakness of the study design. Since ampho-
tericin B at a concentration of 100 mi-
crogram/ml was found not to inhibit fungal 
growth in comparison with a 200 and 300 
microgram/ml over a 6-week period in vitro 
(Shirazi et al., 2008), a 100 microgram/ml 
concentration used in the mentioned study, 
most probably did not reach the required 
concentration in vivo. However, there is still 
controversy regarding the optimum dosage 
of antifungal treatment. According to another 
double-blind, placebo-controlled study, am-
photericin B irrigation improved symptoms 
and endoscopic scores but did not show su-
periority to saline irrigation alone in CRS 
patients over a course of 4 weeks treatment 
(Liang et al., 2008) which is consistent with 
the results of the present study. 
Additionally, a meta-analysis was con-
ducted on the possible therapeutic effects of 
antifungal therapy in CRS. All randomized, 
placebo-controlled trials meeting the eligibil-
ity criteria were entered the study. The re-
sults of the meta-analysis indicated that there 
is no evidence of beneficial effects of topical 
antifungal therapy in management of CRS 
which is in accordance with the results found 
in the present study. However, the authors 
concluded that factors such as diversity in 
the surgical states of the patients, concentra-
tion of antifungals and outcome measure-
ment tools in the studies may have led to 
heterogeneity of treatment outcomes and 
should be considered as well. Thus, no defi-
nite conclusions could be made regarding 
antifungal therapy in CRS (Sacks et al., 
2012). 
 
CONCLUSION 
The use of antifungal treatment for pa-
tients with CRS was not shown to be effec-
tive in the present study. However, this study 
was unique in the fact that most probably no 
one had studied the use of topical flucona-
zole 0.2 % in patients with CRS and the pre-
sent study design allowed that the patients 
were not deprived of their routine treatment. 
Yet, further studies need to be carried out to 
investigate whether modifications in drug 
dose, route of administration, and treatment 
course could improve clinical symptoms and 
objective outcomes of the patients with CRS. 
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